

ORION PHARMA LIMITED AND ITS SUBSIDIARIES
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
AS AT AND FOR NINE MONTH PERIOD ENDED 31 MARCH 2025
(THIRD QUARTER)

ORION PHARMA LIMITED AND ITS SUBSIDIARIES
Condensed Consolidated Statement of Financial Position (Unaudited)
As at 31 March 2025

Particulars	Notes	Amount In BDT	
		31-Mar-25	30-Jun-24
Assets			
Non-Current Assets		37,553,991,517	36,332,123,652
Property, Plant and Equipment	6	20,648,691,560	21,077,115,349
Right of use Assets	7	43,980,965	24,361,873
Capital Work in Progress	8	9,190,888,423	7,163,967,741
Investment in Associates	10	1,735,231,000	2,128,615,000
Other Investments	11	5,935,199,569	5,938,063,689
Current Assets		17,098,304,121	16,853,384,669
Inventories	12	1,640,558,006	1,699,322,929
Trade and Other Receivables	13	14,410,563,308	13,915,714,014
Advances, Deposits & Prepayments	14	911,946,864	1,044,796,936
Fixed Deposit with Banks	15	61,697,354	45,820,338
Cash and Cash Equivalents	16	73,538,588	147,730,452
Total Assets		54,652,295,638	53,185,508,321
Shareholders' Equity and Liabilities			
Shareholders' Equity		20,867,990,670	21,539,576,338
Share Capital	17	2,340,000,000	2,340,000,000
Share Premium		8,016,892,026	8,016,892,026
Reserves	18	3,281,403,266	3,683,345,150
Retained Earnings	19	7,229,695,378	7,499,339,162
Non - Controlling Interest	20	1,491,360,323	1,543,272,725
Total Equity		22,359,350,993	23,082,849,063
Non-Current Liabilities		23,692,516,142	22,336,273,004
Provision for Decommissioning of Assets		143,405,563	143,405,563
Long Term Loan	21	23,137,756,300	21,863,720,817
Lease Obligation	22	31,504,560	13,714,468
Deferred Tax Liability	23	379,849,718	315,432,156
Current Liabilities		8,600,428,503	7,766,386,253
Current portion of Long Term loan	21.1	-	67,349,871
Current Portion of Lease Obligation	22.1	15,407,808	13,943,551
Short term loans	24	546,946,170	556,177,120
Trade and Other Payables	25	7,129,153,729	6,463,692,757
Employee Benefits	26	150,694,892	147,234,452
Unclaimed/Unpaid Dividend		284,884,268	58,675,647
Accrued Expenses	27	473,341,636	459,312,854
Total Equity & Liabilities		54,652,295,638	53,185,508,321
Number of Shares Used to Compute NAV		234,000,000	234,000,000
Net Asset Value (NAV) Including Revaluation Surplus	33	89.18	92.05
Net Asset Value (NAV) Excluding Revaluation Surplus		81.42	84.27

Sd/-
Chairman

Sd/-
Managing Director

Sd/-
Director

Sd/-
Chief Financial Officer

Sd/-
Company Secretary

ORION PHARMA LIMITED
Condensed Statement of Financial Position (Unaudited)
As at 31 March 2025

Particulars	Notes	Amount In BDT	
		31-Mar-25	30-Jun-24
Assets			
Non-Current Assets		29,008,596,754	27,735,689,008
Property, Plant and Equipment	6a	14,887,796,797	15,265,180,705
Right of use Assets	7	43,980,965	24,361,873
Capital Work in Progress	8	9,190,888,423	7,163,967,741
Investment in Subsidiaries	9	1,017,000,000	1,017,000,000
Investment in Associate	10	1,735,231,000	2,128,615,000
Other Investments	11a	2,133,699,569	2,136,563,689
Current Assets		10,485,639,694	10,716,440,347
Inventories	12a	672,116,244	637,639,101
Trade and Other Receivables	13a	8,872,142,060	8,944,679,482
Advances, Deposits & Prepayments	14a	825,436,722	959,959,975
Fixed Deposit with Banks	15	61,697,354	45,820,338
Cash and Cash Equivalents	16a	54,247,314	128,341,450
Total Assets		39,494,236,448	38,452,129,354
Shareholders' Equity and Liabilities			
Shareholders' Equity		14,119,041,293	14,652,306,216
Share Capital	17	2,340,000,000	2,340,000,000
Share Premium		8,016,892,026	8,016,892,026
Reserves	18a	2,933,409,956	3,333,848,346
Retained Earnings	19a	828,739,312	961,565,844
Non-current Liabilities		23,549,110,579	22,192,867,441
Long term loan	21a	23,137,756,300	21,863,720,817
Lease obligation	22	31,504,560	13,714,468
Deferred tax liability	23	379,849,718	315,432,156
Current Liabilities		1,826,084,576	1,606,955,697
Current portion long term loan	21a.1	-	67,349,871
Current portion of finance lease obligation	22.1	15,407,808	13,943,551
Short term loans	24	546,946,170	556,177,120
Trade and other payables	25a	491,584,412	450,267,403
Employee benefits	26a	59,253,515	50,684,141
Unclaimed/Unpaid Dividend		284,884,268	58,675,647
Accrued expenses	27a	428,008,403	409,857,964
Total Equity & Liabilities		39,494,236,448	38,452,129,354
Number of Shares Used to Compute NAV		234,000,000	234,000,000
Net Asset Value (NAV) Including Revaluation Surplus	33a	60.34	62.62
Net Asset Value (NAV) Excluding Revaluation Surplus		54.57	56.83

Sd/-
Chairman

Sd/-
Managing Director

Sd/-
Director

Sd/-
Chief Financial Officer

Sd/-
Company Secretary

ORION PHARMA LIMITED AND ITS SUBSIDIARIES
Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income (Unaudited)
For Nine Month Period Ended 31 March 2025

Particulars	Notes	Amount In BDT			
		July 2024 to March 2025	July 2023 to March 2024	January to March 2025	January to March 2024
Revenue from Net Sales	28	3,352,010,387	7,780,497,718	845,073,515	2,035,298,993
Cost of Goods Sold		(1,213,812,662)	(1,295,617,596)	(388,580,852)	(408,709,141)
Cost of Power Generation		(892,898,341)	(4,758,712,106)	(40,863,656)	(1,111,356,745)
Gross Profit		1,245,299,383	1,726,168,016	415,629,007	515,233,108
Operating Expenses		(1,036,083,546)	(1,134,077,881)	(343,442,180)	(338,015,075)
General & Administrative Expenses		(361,583,235)	(437,872,389)	(101,645,804)	(142,038,333)
Selling & Distribution Expenses		(674,500,311)	(696,205,492)	(241,796,376)	(195,976,742)
Profit from Operation		209,215,837	592,090,135	72,186,827	177,218,032
Financial Expenses	29	(235,507,570)	(100,063,016)	(59,865,499)	(51,171,079)
Non Operating Income/ (Loss)	30	16,015,459	17,123,676	7,718,405	3,337,809
Net Profit from Operation		(10,276,274)	509,150,795	20,039,734	129,384,763
Workers Profit Participation Fund		(8,569,375)	(24,245,276)	(3,455,784)	(6,161,179)
Net Profit before Tax		(18,845,649)	484,905,519	16,583,950	123,223,584
Income Tax		(80,640,364)	(88,754,684)	(25,681,239)	(30,801,103)
Current Tax (Expenses)/Income	31	(15,302,738)	(105,314,399)	(5,088,665)	(36,238,451)
Deferred Tax (Expenses)/Income		(65,337,625)	16,559,715	(20,592,574)	5,437,348
Net Profit after Tax		(99,486,012)	396,150,836	(9,097,289)	92,422,481
Share of Profit from Associate		6,202,000	6,423,500	1,639,100	1,727,700
Net Profit		(93,284,012)	402,574,336	(7,458,189)	94,150,180
Less: Non Controlling Interest (share of operating profit)		51,912,402	(16,440,196)	13,282,310	5,066,237
Net Profit after Tax before Other Comprehensive Income		(41,371,610)	386,134,140	5,824,121	99,216,418
Other Comprehensive Income		(396,215,408)	787,221,030	(155,839,056)	678,827,475
Fair Value Gain of Marketable Securities		(2,865,470)	(4,458,339)	709,809	(2,602,789)
Fair Value Gain on Investment in Associate		(394,584,467)	790,089,372	(156,834,303)	680,950,155
Share of Other Comprehensive Income		314,467	444,128	145,203	(14,855)
Deferred tax Income (Expenses) on Revaluation Surplus of PPE & Fair Value Changes of Marketable securities		920,062	1,145,869	140,236	494,964
Total Comprehensive Income Attributable to Ordinary Shareholders		(437,587,018)	1,173,355,170	(150,014,935)	778,043,893
Number of Shares Used to Compute EPS		234,000,000	234,000,000	234,000,000	234,000,000
Earnings Per Share (EPS)	32	(0.18)	1.65	0.02	0.42

Sd/-
Chairman

Sd/-
Managing Director

Sd/-
Director

Sd/-
Chief Financial Officer

Sd/-
Company Secretary

ORION PHARMA LIMITED
Condensed Statement of Profit or Loss and Other Comprehensive Income (Unaudited)
For Nine Month Period Ended 31 March 2025

Particulars	Notes	Amount In BDT			
		July 2024 to March 2025	July 2023 to March 2024	January to March 2025	January to March 2024
Revenue from Net Sales	28.a	2,534,439,608	2,843,953,559	845,073,515	894,353,582
Cost of Goods Sold		(1,213,812,662)	(1,295,617,596)	(388,580,852)	(408,709,141)
Gross Profit		1,320,626,945	1,548,335,963	456,492,663	485,644,441
Operating Expenses		(996,953,844)	(1,062,258,925)	(332,251,409)	(296,324,452)
General & Administrative Expenses		(322,453,533)	(366,053,433)	(90,455,033)	(100,347,710)
Selling & Distribution Expenses		(674,500,311)	(696,205,492)	(241,796,376)	(195,976,742)
Profit from Operation		323,673,101	486,077,038	124,241,255	189,319,988
Financial Expenses	29.a	(159,731,686)	(74,578,534)	(59,388,194)	(44,463,672)
Non Operating Income/ (Loss)	30.a	16,015,459	14,917,546	7,718,405	1,131,679
Net Profit from Operation		179,956,874	426,416,050	72,571,466	145,987,995
Workers Profit Participation Fund		(8,569,375)	(20,305,526)	(3,455,784)	(6,951,809)
Net Profit before Tax		171,387,499	406,110,524	69,115,682	139,036,186
Income Tax		(80,640,364)	(88,754,684)	(25,681,239)	(30,801,103)
Current Tax (Expenses)/Income	31	(15,302,738)	(105,314,399)	(5,088,665)	(36,238,451)
Deferred Tax (Expenses)/Income		(65,337,625)	16,559,715	(20,592,574)	5,437,348
Net Profit after Tax		90,747,135	317,355,840	43,434,443	108,235,083
Share of Profit from Associates		6,202,000	6,423,500	1,639,100	1,727,700
Net Profit after Tax before Other Comprehensive Income		96,949,135	323,779,340	45,073,543	109,962,783
Other Comprehensive Income		(396,215,408)	787,221,030	(155,839,056)	678,827,475
Fair Value Gain of Marketable Securities		(2,865,470)	(4,458,339)	709,809	(2,602,789)
Fair Value Gain on Investment in Associate		(394,584,467)	790,089,372	(156,834,303)	680,950,155
Share of Other Comprehensive Income		314,467	444,128	145,203	(14,855)
Deferred tax Income (Expenses) on Revaluation Surplus of PPE & Fair Value Changes of Marketable securities		920,062	1,145,869	140,236	494,964
Total Comprehensive Income attribute to Ordinary Shareholders		(299,266,273)	1,111,000,370	(110,765,512)	788,790,258
Number of Shares Used to Compute EPS		234,000,000	234,000,000	234,000,000	234,000,000
Earnings Per Share (EPS)	32.a	0.41	1.38	0.19	0.47

Sd/-
Chairman

Sd/-
Managing Director

Sd/-
Director

Sd/-
Chief Financial Officer

Sd/-
Company Secretary

ORION PHARMA LIMITED AND ITS SUBSIDIARIES
Condensed Consolidated Statement of Changes in Equity (Unaudited)
For Nine Month Period Ended 31 March 2025

Amount in BDT

Particulars	Ordinary Share Capital	Share Premium	Reserves	Retained Earnings	Total	Non controlling Interest	Total
Balance at 01 July 2024	2,340,000,000	8,016,892,026	3,683,345,150	7,499,339,162	21,539,576,338	1,543,272,725	23,082,849,063
Net Profit after Tax	-	-	-	(41,371,610)	(41,371,610)	(51,912,402)	(93,284,012)
Cash Dividend for the year 2023-2024				(234,000,000)	(234,000,000)		(234,000,000)
Fair Value Gain / (Loss) on Investment in Associate			(394,584,467)	-	(394,584,467)	-	(394,584,467)
Fair Value (Loss)/Gain on Marketable Securities			(2,865,470)	-	(2,865,470)	-	(2,865,470)
Adjustment for sale of Mkt. Securities			1,350	-	1,350	-	1,350
Share of Other Comprehensive Income			314,467	-	314,467	-	314,467
Adjustment of Deferred tax on Revaluation Surplus			920,062	-	920,062	-	920,062
Depreciation on Revaluation Surplus			(5,727,826)	5,727,826	-	-	-
Balance at 31 March 2025	2,340,000,000	8,016,892,026	3,281,403,266	7,229,695,378	20,867,990,670	1,491,360,323	22,359,350,993

For Nine Month Period Ended 31 March 2024

Particulars	Ordinary Share Capital	Share Premium	Reserves	Retained Earnings	Total	Non controlling Interest	Total
Balance at 01 July 2023	2,340,000,000	8,016,892,026	3,067,212,663	7,400,327,363	20,824,432,052	1,509,624,870	22,334,056,922
Net Profit after Tax	-	-	-	386,134,140	386,134,140	16,440,196	402,574,336
Cash Dividend for the year 2022-2023				(234,000,000)	(234,000,000)		(234,000,000)
Fair Value Gain / (Loss) on Investment in Associate			790,089,372	-	790,089,372	-	790,089,372
Fair Value (Loss)/Gain on Marketable Securities			(4,458,339)	-	(4,458,339)	-	(4,458,339)
Adjustment for sale of Mkt. Securities			40,203	-	40,203	-	40,203
Share of Other Comprehensive Income			444,128	-	444,128	-	444,128
Adjustment of Deferred tax on Revaluation Surplus			1,145,869	-	1,145,869	-	1,145,869
Adjustment for Right of use Assets				822,860	822,860		822,860
Depreciation on Revaluation Surplus			(10,530,382)	10,530,382			
Balance at 31 March 2024	2,340,000,000	8,016,892,026	3,843,943,514	7,563,814,744	21,764,650,285	1,526,065,066	23,290,715,351

Sd-
Chairman

Sd-
Managing Director

Sd-
Director

Sd-
Chief Financial Officer

Sd-
Company Secretary

ORION PHARMA LIMITED
Condensed Statement of Changes in Equity (Unaudited)
For Nine Month Period Ended 31 March 2025

Particulars	Amount in BDT				
	Ordinary Share Capital	Share Premium	Reserves	Retained Earnings	Total
Balance at 01 July 2024	2,340,000,000	8,016,892,026	3,333,848,346	961,565,844	14,652,306,216
Net Profit after Tax	-	-	-	96,949,135	96,949,135
Cash Dividend for the year 2023-2024				(234,000,000)	(234,000,000)
Fair Value Gain /(Loss)on Investment in Associate	-	-	(394,584,467)	-	(394,584,467)
Fair Value (Loss)/Gain on Marketable Securities	-	-	(2,865,470)	-	(2,865,470)
Adjustment for sale of Mkt. Securities	-	-	1,350	-	1,350
Share of Other Comprehensive Income	-	-	314,467	-	314,467
Adjustment of Deferred tax on Revaluation Surplus	-	-	920,062	-	920,062
Depreciation on Revaluation Surplus	-	-	(4,224,332)	4,224,332	-
Balance at 31 March 2025	2,340,000,000	8,016,892,026	2,933,409,956	828,739,312	14,119,041,293

For Nine Month Period Ended 31 March 2024

Particulars	Ordinary Share Capital	Share Premium	Reserves	Retained Earnings	Total
Balance at 01 July 2023	2,340,000,000	8,016,892,026	2,709,933,620	973,857,096	14,040,682,742
Net Profit after Tax	-	-	-	323,779,340	323,779,340
Cash Dividend for the year 2022-2023				(234,000,000)	(234,000,000)
Fair Value Gain /(Loss)on Investment in Associate	-	-	790,089,372	-	790,089,372
Fair Value (Loss)/Gain on Marketable Securities	-	-	(4,458,339)	-	(4,458,339)
Adjustment for sale of Mkt. Securities	-	-	40,203	-	40,203
Share of Other Comprehensive Income	-	-	444,128	-	444,128
Adjustment of Deferred tax on Revaluation Surplus	-	-	1,145,869	-	1,145,869
Adjustment for Right of use Assets				822,860	822,860
Depreciation on Revaluation Surplus	-	-	(4,693,703)	4,693,703	-
Balance at 31 March 2024	2,340,000,000	8,016,892,026	3,492,501,151	1,069,152,998	14,918,546,175

**Sd-
Chairman**

**Sd-
Managing Director**

**Sd-
Director**

**Sd-
Chief Financial Officer**

**Sd-
Company Secretary**

ORION PHARMA LIMITED AND ITS SUBSIDIARIES
Condensed Consolidated Statement of Cash Flows (Unaudited)
For Nine Month Period Ended 31 March 2025

Particulars	Amount In BDT	
	July 2024 to March 2025	July 2023 to March 2024
A. Cash Flows from Operating Activities :		
Cash Received from Customers	3,223,297,591	10,060,939,225
Cash Paid to Suppliers	(1,195,692,445)	(8,161,815,736)
Cash Payment for Operating Expenses	(756,597,585)	(1,047,165,305)
Cash Generated from Operation	1,271,007,561	851,958,183
Income Taxes Paid	(37,529,764)	(127,964,951)
Net Cash Generated/(Used) from Operating Activities	1,233,477,797	723,993,232
B. Cash Flows from Investing Activities :		
Acquisition of Property, Plant & Equipment	(42,583,898)	(15,962,297)
Proceeds from sales of PPE	-	1,270,000
Capital Work in Progress	(2,026,920,682)	(1,882,357,105)
Investment in Subsidiaries, Associate & Others	(5,900,665)	951,383,961
Interest, Dividend & Other Income	16,015,459	13,705,222
Net Cash Received/(Used) from Investing Activities	(2,059,389,786)	(931,960,220)
C. Cash Flows from Financing Activities :		
Long Term Loan Received/ (Repaid)	1,206,685,612	(809,599,256)
Short Term Loan Received/ (Repaid)	(198,379,822)	1,285,974,921
Lease obligation	(13,286,718)	(17,519,046)
Financial expenses paid	(235,507,570)	(97,856,886)
Dividend paid	(7,791,379)	(77,302,448)
Net Cash Received/(Used) from Financing Activities	751,720,123	283,697,285
Net Increase /(Decrease) in Cash & Cash Equivalents (A+B+C)	(74,191,866)	75,730,297
Cash & Cash Equivalents at the beginning of the period	147,730,453	130,107,384
Cash & Cash Equivalents at the end of the period	73,538,588	205,837,681
Number of Shares Used to Compute NOCFPS	234,000,000	234,000,000
Net Operating Cash Flow Per Share	5.27	3.09

Sd-
Chairman

Sd-
Managing Director

Sd-
Director

Sd-
Chief Financial Officer

Sd-
Company Secretary

ORION PHARMA LIMITED
Condensed Statement of Cash Flows (Unaudited)
For Nine Month Period Ended 31 March 2025

Particulars	Amount In BDT	
	July 2024 to March 2025	July 2023 to March 2024
A. Cash Flows from Operating Activities :		
Cash Received from Customers	2,602,316,678	2,793,586,189
Cash paid to Suppliers	(839,966,757)	(1,076,407,652)
Cash Payment for Operating Expenses	(756,597,585)	(1,047,165,305)
Cash Generated from Operation	1,005,752,336	670,013,232
Income Taxes Paid	(37,529,764)	(127,964,951)
Net Cash Generated/(Used) from Operating Activities	968,222,572	542,048,281
B. Cash Flows from Investing Activities :		
Acquisition of Property, Plant & Equipment	(42,155,698)	(15,880,697)
Proceeds from sales of PPE	-	1,270,000
Capital Work in Progress	(2,026,920,682)	(1,882,357,105)
Investment in Subsidiaries, Associate, Securities & Others	(5,900,665)	951,383,961
Interest, Dividend & Other Income	16,015,459	13,705,223
Net Cash Received/(Used) from Investing Activities	(2,058,961,586)	(931,878,619)
C. Cash Flows from Financing Activities :		
Long Term Loan Received/ (Repaid)	1,206,685,612	(550,150,826)
Short Term Loan Received/ (Repaid)	(9,230,951)	1,280,238,715
Lease obligation	(13,286,718)	(17,519,046)
Dividend paid	(7,791,379)	(77,302,448)
Interest Paid	(159,731,686)	(74,578,534)
Net Cash Received/(Used) from Financing Activities	1,016,644,878	560,687,861
Net Increase /(Decrease) in Cash & Cash Equivalents (A+B+C)	(74,094,136)	170,857,523
Cash & Cash Equivalents at the beginning of the period	128,341,450	24,827,980
Cash & Cash Equivalents at the end of the period	54,247,314	195,685,503
Number of Shares Used to Compute NOCFPS	234,000,000	234,000,000
Net Operating Cash Flow Per Share	4.14	2.32

Sd-
Chairman

Sd-
Managing Director

Sd-
Director

Sd-
Chief Financial Officer

Sd-
Company Secretar

ORION PHARMA LIMITED AND ITS SUBSIDIARIES
Selected Explanatory Notes to the Condensed Consolidated Financial Statements
For Nine Month Period Ended 31 March 2025 (Third Quarter)

1 Reporting Entity

1.1 Background of the Entity

Orion Pharma Limited earlier called Orion Laboratories Limited was incorporated in 1965 as a private limited company. The Company was converted into a public limited company on 24 July 2010. The registered office of the company is at 153-154 Tejgaon I/A Dhaka-1208 Bangladesh.

The Company is listed both with Dhaka Stock Exchange Limited (DSE) and Chittagong Stock Exchange Limited (CSE) on 20 March 2013.

1.2 Nature of Business

Orion Pharma Limited is engaged in the creation and discovery development manufacturing and marketing of pharmaceutical products including vaccines and health- related consumer products.

1.3 Subsidiary Companies

1.3.1 Orion Power Meghnaghat Limited

Orion Power Meghnaghat Ltd. was incorporated on 30 June 2010 as a public limited company under the Companies Act 1994 with authorized share capital of Tk. 4000000000 divided into 400000000 Ordinary shares of Tk. 10 each. The company implemented a 100 MW HFO Power based Plant on quick rental basis in Meghnaghat Dhaka to supply electricity to national grid with machineries and equipment supplied by Wartsila OY Finland. Orion Pharma Ltd. holds 95% of equity share of this company directly.

The company has set up a 100 MW HFO Power Plant on quick rental basis in Meghnaghat Sonargaon Narayanganj with machineries and equipment's supplied by Wartsila Finland OY for generation and supply of electricity. The company has signed the contract with Bangladesh Power Development Board (hereinafter referred as BPDB) acting as an off taker to supply power to them solely under the contract No. 09755 executed on June 30 2010. According to the said contract the Government will purchase the power for a period of five (5) years commencing from May 08 2011. The contract has been extended for further five (5) years effective from May 09 2016 vide memo no- 27.00.0000.071.14.035.2013.535 dated 01 December 2016. The contract then expired on 07 May 2021. The government renewed the contract for two (2) years effective from 24 March 2022 vide memo no - 27.11.0000.101.14.020.22-1697 dated: 10 April 2022. The purpose of this contract is to supply of Net Energy Output under the terms and conditions provided "No Electricity No Payment and also without any guaranteed Minimum Off-take" basis by Rental Power Company by BPDB which expired on 23 March 2024. As per memo No.: 27.11.0000.101.14.020.24-1099 dated: 29 April 2024 the company was instructed to resume and continue operation.

1.3.2 Dutch Bangla Power & Associates Limited

Dutch Bangla Power & Associates Ltd. was incorporated on 1 July 2010 as a public limited company under the Companies Act 1994 with authorized share capital of Tk. 1000000000 divided into 100000000 ordinary shares of Tk. 10 each. The Company was awarded by the Government of Bangladesh and BPDB to implement 100 MW HFO Power Plant on quick rental basis in Siddhirganj Narayanganj to supply electricity to national grid with machineries and equipment supplied by Wartsila OY Finland. Orion Pharma Ltd. holds 67% of equity share of this Company.

The company has set up a 100 MW HFO Power Plant on quick rental basis in Siddhirganj Narayanganj with machineries and equipments supplied by Wartsila Finland OY for generation and supply of electricity. The company has signed the contract with Bangladesh Power Development Board (hereinafter referred as BPDB) acting as an off taker to supply power to them solely under the contract No. 09756 executed on July 01 2010. According to the said contract the Government will purchase the power for a period of five (5) years commencing from July 21 2011. The contract has been extended for further five (5) years effective from 22 July 2016 vide memo no- 27.00.0000.071.14.122.2010.534 dated 01 December 2016. The contract then expired on 22 July 2021. The government renewed the contract for two (2) years effective from 24 March 2024 vide memo no - 27.11.0000.101.14.020.22-1696 dated: 10 April 2024. The purpose of this contract is to supply of Net Energy Output under the terms and conditions provided "No Electricity No Payment and also without any guaranteed Minimum Off-take" basis by Rental Power Company by BPDB which expired on 23 March 2024. As per memo No.: 27.11.0000.101.14.020.24-1100 dated: 29 April 2024 the company was instructed to resume and continue operation.

1.4 Associate Company Orion Infusion Limited

Orion Infusion Limited is a public limited company incorporated in Bangladesh on May 05 1983 and is now operating under the banner of Orion Group. Other shareholders of the company are sponsor shareholders foreign investors financial institutions and general public.

The Company was listed with Dhaka Stock Exchange Limited (DSE) on 05 October 1994 and Chittagong Stock Exchange Limited (CSE) on 22 September 1996. Orion Pharma Ltd. holds 21.76 % of equity share of this company directly.

2 Basis of Preparation

2.1 Statement of Compliance

These Condensed Interim Financial Statements of the company comprised the company's and its subsidiaries (together referred to as the 'Group' and individually as 'Group entities') and the Group's interest in associates have been prepared in accordance with International Financial Reporting Standards (IFRSs) adopted by the Institute of Chartered Accountants of Bangladesh (ICAB) in particular International Accounting Standard (IAS) 34: Interim Financial Reporting the Companies Act 1994 Securities and Exchange Rules 1987 and other applicable laws and regulations.

2.2 Components of the Condensed Financial Statements

According to IAS-34 'Interim Financial Reporting' these interim financial statements include the following components-

- i. Condensed Consolidated Statement of Financial Position
- ii. Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income
- iii. Condensed Consolidated Statement of Changes in Equity
- iv. Condensed Consolidated Statement of Cash Flows
- v. Selected Explanatory Notes to the Condensed Consolidated Financial Statements

2.3 Basis of Measurement

The financial statements have been prepared on historical cost basis except for certain assets which are stated either at revalued amount or fair market value.

2.4 Functional and Presentation Currency

The financial statements are prepared and presented in Bangladesh Taka (Taka/Tk./BDT) which is the company's functional and presentation currency. All amounts have been rounded off to the nearest integer.

2.5 Reporting Period

These Condensed Interim Financial Statements of the company cover nine month period from 1 July 2024 to 31 March 2025.

2.6 Date of Authorization

The financial statements were authorized for issue by the Board of Directors in its meeting held on 29 April 2025 for publication.

2.7 Events after the reporting period

Information regarding subsidiary companies

For this quarter there was no such issue.

3 Accounting Policies and Methods of Computations

The accounting policies and methods of computations followed in preparing these financial statements are same as those used in the annual financial statements prepared and published for the year ended 30 June 2024.

4 Subsequent Events

No material events occurred after the reporting date non-disclosure of which could affect the ability of the users of the financial statements to make proper evaluation and decision.

5 Acquisition of Property Plant & Equipments of Orion Pharma Ltd. and its subsidiaries during the Period.

Discloser as per BSEC Notification No. BSEC/CMRRCD/2006-158/208/Admin/81 Dated: 20 June 2018.

SL No.	Particulars	Amount in BDT	
		31-Mar-25	30-Jun-24
i	Factory & Office Building	35,541,604	52,800
ii	Plant & Machinery	4,450,005	8,931,185
iii	Furniture & Fixtures	6,100	121,610
iv	Office Equipment	2,564,322	6,588,593
v	Vehicle	-	1,953,500
vi	Road & Road Development	21,866	1,946,534
Total		42,583,898	19,594,222

SL No.	Particulars	Amount in BDT	
		31-Mar-25	30-Jun-24

6. Property plant and equipment

Opening balance	21,077,115,349	13,317,799,927
Add: Addition during the period	42,583,898	19,594,222
Transfer from Capital work in Progress	-	8,310,620,491
Less: Sale /disposal during the period	-	(57,677)
	21,119,699,247	21,647,956,963
Less: Depreciation charged during the period	(471,007,688)	(570,841,614)
Written down value	20,648,691,560	21,077,115,349

6a. Property plant and equipment

Opening balance	15,265,180,705	7,228,006,743
Add: Addition during the period	42,155,698	19,442,622
Transfer from Capital work in Progress	-	8,310,620,491
Less: Sale /disposal during the period	-	(57,677)
	15,307,336,403	15,558,012,179
Less: Depreciation charged during the period	(419,539,606)	(292,831,474)
Written down value	14,887,796,797	15,265,180,705

7. Right of use assets

Opening Balance	143,942,706	143,366,149
Add: Addition during the period	32,541,067	4,772,731
	176,483,773	148,138,880
Less: Disposal/ adjustment	-	(4,196,174)
	176,483,773	143,942,706
Amortization		
Opening balance	119,580,834	101,726,647
Addition during the period	12,921,974	17,854,187
	132,502,808	119,580,834
Written down value	43,980,965	24,361,873

13

SL No.	Particulars	Amount in BDT	
		31-Mar-25	30-Jun-24
11a.2	Investment in non-quoted shares		
	Orion Power Khulna Limited.	500,000	500,000
	Orion Power Dhaka Limited.	500,000	500,000
	ICB Islami Bank Limited	246,000	246,000
	Orion Infrastructure Limited.	2,117,209,676	2,117,209,676
	Orion Power Unit - 2 Dhaka Ltd.	1,785,000	1,785,000
		2,120,240,676	2,120,240,676
12.	Inventories		
	Raw materials	216,200,589	223,558,583
	Packing materials	126,625,791	112,835,551
	Work-in-process	24,572,739	33,940,589
	Finished goods	157,999,246	152,492,482
	Printing Stationeries	8,153,817	16,169,876
	Promotional materials	21,257,678	26,715,542
	Material in transit	117,306,384	71,926,478
	Spare parts	513,571,744	483,494,642
	Inventory HFO & LFO	454,870,019	578,189,186
		1,640,558,006	1,699,322,929
12.a	Inventories		
	Raw materials	216,200,589	223,558,583
	Packing materials	126,625,791	112,835,551
	Work-in-process	24,572,739	33,940,589
	Finished goods	157,999,246	152,492,482
	Printing Stationeries	8,153,817	16,169,876
	Promotional materials	21,257,678	26,715,542
	Material in transit	117,306,384	71,926,478
		672,116,244	637,639,101
13.	Trade & other receivables		
	Trade receivables	4,338,790,525	4,210,077,730
	Other receivables (Note-13.1)	10,071,772,782	9,705,636,284
		14,410,563,308	13,915,714,014

Trade receivables are unsecured considered good and recoverable within one year. Classification schedules as required by schedule XI of Companies Act 1994 are as follows:

Ageing of the above balance is as follows:

Below 180 days	4,338,790,525	4,210,077,730
Above 180 days	-	-
	4,338,790,525	4,210,077,730

SL. No.	Particulars	Amount in BDT	
		31-Mar-25	30-Jun-24
I	Trade receivables considered good in respect of which the company is fully secured	4,338,790,525	4,210,077,730
II	Trade receivables considered good in respect of which the company holds no security other than the debtor personal security	-	-
III	Trade receivables considered doubtful or bad	-	-
IV	Trade receivables due by any director or other officer of the company	-	-
V	Trade receivables due by common management	-	-
VI	The maximum amount of receivable due by any director or other officer of the company	-	-
	Total	4,338,790,525	4,210,077,730

SL No.	Particulars	Amount in BDT	
		31-Mar-25	30-Jun-24
13.1	Other receivables		
	Claim receivables insurance & others	4,384,176	4,352,154
	Dividend receivable	5,316,000	4,430,000
	Interest on FDR	821,748	578,164
	Other receivables	1,238,082,230	1,220,885,230
	Current account with other related companies (Note. 13.1.1)	8,823,168,628	8,475,390,736
		10,071,772,782	9,705,636,284

13.1.1 Current account with other related companies

Noakhali Gold Food Ltd.	10,859,928	10,859,928
Orion Properties Ltd.	23,550,142	23,550,142
Orion Gas Limited	90,916,636	90,911,272
Orion Power Khulna Ltd.	1,076,950,154	1,084,624,104
Orion Power Dhaka Ltd.	2,370,355,084	2,370,263,896
Jafflong Tea Company Ltd.	73,302,850	73,302,850
Orion Agro Product Ltd.	275,775,350	275,775,350
Interior Accom Consortium Ltd.	85,407,892	85,407,892
Digital Power & Associate Ltd.	1,188,699,691	1,045,385,127
Orion Footwear Ltd.	260,454,807	258,954,807
Panbo Bangla Mashroom Ltd.	38,128,200	38,128,200
Orion Power Unit 2 Dhaka Ltd.	952,316,764	952,331,473
Orion Home Appliance Ltd.	139,326,926	139,697,496
Orion Hospitals Ltd.	26,222,300	26,222,300
Orion Power Rupsha Ltd.	122,429,699	122,929,699
Energion Renewable (BD) Ltd.	683,407,792	683,407,792
Orion Quaderia Textiles Ltd.	187,910,000	187,910,000
Orion Tea Company Ltd	379,569,748	379,357,868
SAZKA Natural Care Ltd.	108,663,500	108,663,500
Orion Power Sonargaon Ltd	679,339,166	496,125,040
Orion Knit Textiles Ltd.	21,582,000	21,582,000
Orion Infrastructure Limited	28,000,000	-
	8,823,168,628	8,475,390,736

13.a Trade & other receivables

Trade receivables	304,441,411	372,318,481
Other receivables (Note - 13a.1)	8,567,700,649	8,572,361,001
	8,872,142,060	8,944,679,482

Trade receivables are unsecured considered good and recoverable within one year. Classification schedules as required by schedule XI of Companies Act 1994 are as follows:

Ageing of the above balance is as follows:

Below 180 days	304,441,411	372,318,481
Above 180 days	-	-
	304,441,411	372,318,481

SL No	Particulars	Amount in BDT	
		31-Mar-25	30-Jun-24
I	Trade receivables considered good in respect of which the company is fully secured	304,441,411	372,318,481
II	Trade receivables considered good in respect of which the company holds no security other than the debtor personal security		-
III	Trade receivables considered doubtful or bad		-
IV	Trade receivables due by any director or other officer of the company		-
V	Trade receivables due by common management		-
VI	The maximum amount of receivable due by any director or other officer of the company		-
	Total	304,441,411	372,318,481

SL No.	Particulars	Amount in BDT	
		31-Mar-25	30-Jun-24
13a.1	Other receivables		
	Claim receivables insurance & others	4,384,176	4,352,154
	Dividend receivable	5,316,000	4,430,000
	Interest on FDR	821,748	578,164
	Other receivables	938,766,019	938,766,019
	Current account with subsidiaries (13a.1.1)	346,805,959	346,395,908
	Current account with other related companies (13a.1.2)	7,271,606,747	7,277,838,756
		8,567,700,649	8,572,361,001
13a.1.1	Current account with subsidiaries		
	Dutch Bangla Power & Associates Limited.	346,805,959	346,395,908
		346,805,959	346,395,908
13a.1.2	Current account with other related companies		
	Orion Properties Ltd.	21,780,585	21,780,585
	Orion Power Khulna Ltd.	1,076,950,154	1,084,624,104
	Orion Power Dhaka Ltd.	2,284,334,998	2,284,243,810
	Interior Accom Consortium Ltd.	118,564,892	118,564,892
	Orion Agro Product Ltd.	267,922,512	267,922,512
	Orion Power Unit -2 Dhaka Ltd.	1,062,254,582	1,062,250,503
	Digital Power & Associates Ltd.	196,111,884	196,111,884
	Orion Hospitals Ltd.	21,222,300	21,222,300
	Energon Renewables (BD) Ltd.	698,707,792	698,707,792
	Orion Home Appliances Ltd.	131,519,430	131,890,000
	SAZKA Natural Care Ltd.	108,663,500	108,663,500
	Orion Gas Ltd.	41,716,636	41,711,272
	Panbo Bangla Mushroom Ltd	38,128,200	38,128,200
	Orion Footwear Ltd.	121,792,645	120,292,645
	Orion Tea Company Ltd	379,569,748	379,357,868
	Orion Power Sonargaon Ltd	501,980,411	501,980,411
	Jafflong Tea Company Ltd.	70,894,479	70,894,479
	Orion Knit Textiles Ltd.	21,582,000	21,582,000
	Orion Quaderia Textiles Ltd	107,910,000	107,910,000
		7,271,606,747	7,277,838,756

SL No.	Particulars	Amount in BDT	
		31-Mar-25	30-Jun-24
14.	Advances deposits and prepayments		
	Advances:		
	Advance income tax (Note-14.1)	330,840,224	295,975,607
	Advance imprest money	225,500	123,500
	Advance motor cycle	4,640,783	6,437,957
	Advance - car loan	284,808	433,522
	Collection advance	15,600,604	11,097,734
	Advance to C&F agents	4,054,775	6,662,649
	Advance office rent	3,364,413	2,822,634
	Advance against land purchase	97,260,635	97,260,635
	Advance to employee	6,046,072	8,129,682
	Other advance	89,206	1,190,687
	Advance Cash Purchase	127,936	852,328
	Advance to Supplier	195,264,865	173,158,820
	Machinery in Transit	15,042,754	185,425,315
		672,842,574	789,571,070
	Deposits:		
	Earnest money	9,863,415	9,808,415
	Security deposit	42,272,933	48,059,193
	Bank guarantee	58,530,166	58,477,623
	Lease deposit	-	254,133
	L/C Margin & Balance	127,972,434	127,972,434
		238,638,949	244,571,798
	Prepayments:		
	Insurance premium	465,342	110,830
	Bank guranteecommission & charge	-	10,543,237
		465,342	10,654,068
		911,946,864	1,044,796,936
14.1	Advance income tax		
	Opening balance	295,975,607	253,914,819
	Add: Addition during the period	34,864,616	42,060,789
	Closing balance	330,840,224	295,975,607
14.a	Advances deposits & prepayments		
	Advances:		
	Advance income tax (Note -14a.1)	327,942,279	293,412,515
	Advance imprest money	225,500	123,500
	Motor cycle advance	4,640,783	6,437,957
	Advance - car loan	284,808	433,522
	Collection advance	15,600,604	11,097,734
	Advance to C&F agents	4,054,775	6,662,649
	Advance office rent	3,364,413	2,822,634
	Advance against land purchase	97,260,635	97,260,635
	Advance to Employee	5,286,176	7,808,198
	Others Advance	89,206	1,190,687
	Advance Cash Purchase	127,936	852,328
	Advance Paid to Suppliers	167,964,715	156,947,314
	Machinery in Transit	15,042,754	185,425,315
		641,884,584	770,474,987
	Deposits		
	Earnest money	9,863,415	9,808,415
	Security deposit	42,272,933	48,059,193
	Bank guarantee	3,715,790	3,663,247
	Lease deposit	-	254,133
	L/C Margin & Balance	127,700,000	127,700,000
		183,552,138	189,484,988
		825,436,722	959,959,975

SL No.	Particulars	Amount in BDT	
		31-Mar-25	30-Jun-24
14a.1	Advance income tax		
	Opening balance	293,412,515	251,801,807
	Addition during the period	34,529,764	41,610,707
	Closing balance	327,942,279	293,412,515
15.	Fixed deposit with banks		
	Social Islami Bank Limited. Principal Branch Dhaka.	11,022,211	10,473,026
	Agrani Bank Ltd.	50,675,144	35,347,312
		61,697,354	45,820,338
16.	Cash & cash equivalents		
	Cash in hand (Note -16.1)	12,756,233	5,608,660
	Cash at B/O account (Note -16.2)	65,522	66,872
		12,821,755	5,675,532
	Balance with banks on account		
	Current account	54,341,017	133,925,252
	Short term deposit account	6,375,817	8,129,669
		60,716,833	142,054,920
		73,538,588	147,730,452
16.1	Cash in hand		
	Head office	1,703,229	2,400,048
	Depot office	11,053,004	3,208,613
		12,756,233	5,608,660
16.2	Cash at B/O account		
	Bank Asia Securities Limited.	19,549	19,999
	Jahan Securities Limited.	624	1,074
	LankaBangla Securities Ltd.	42,249	42,699
	Shanta Securities Ltd.	3,100	3,100
		65,522	66,872
16.a	Cash and cash equivalents		
	Cash in hand (Note -16a.1)	8,359,027	3,394,262
	Cash at B/O account (Note -16a.2)	62,422	63,772
		8,421,449	3,458,034
	Cash at Bank:		
	Current account	39,450,049	116,753,748
	Short term deposit account	6,375,817	8,129,669
		45,825,865	124,883,416
		54,247,314	128,341,450
16a.1	Cash in hand		
	Head office - central cash & main cash	355,462	1,414,262
	Depot office - petty cash	8,003,566	1,980,000
		8,359,027	3,394,262
16a.2	Cash at B/O account		
	Bank Asia Securities Limited	19,549	19,999
	Jahan Securities Limited	624	1,074
	LankaBangla Securities Ltd.	42,249	42,699
		62,422	63,772

SL No.	Particulars	Amount in BDT	
		31-Mar-25	30-Jun-24

17. Share capital

Authorized capital

500000000 ordinary shares of Tk. 10 each

5,000,000,000

5,000,000,000

Issued subscribed and paid-up capital

234000000 ordinary shares of Tk. 10 each

2,340,000,000

2,340,000,000

Shareholding position of the company

Range of Shareholding	Number of Shareholders	Number of Shares	% of holding	
			31-Mar-25	30-Jun-24
Up to 500 Shares	25,157	3,627,908	1.55%	1.66%
501 to 5000 Shares	12,279	23,258,875	9.94%	9.49%
5001 to 10000 Shares	2,061	15,246,621	6.52%	5.92%
10001 to 20000 Shares	1,165	16,762,005	7.16%	6.53%
20001 to above	1,048	175,104,591	74.83%	76.40%
Total	41,710	234,000,000	100%	100%

Categories of shareholders	Number of Shareholders	Number of Shares	% of holding	
			31-Mar-25	30-Jun-24
Sponsors	5	74,841,600	31.98%	31.98%
Foreign Investor	181	229,854	0.10%	0.08%
Financial institutions	632	50,509,195	21.59%	21.56%
General public	40,892	108,419,351	46.33%	46.38%
Total	41,710	234,000,000	100%	100%

Orion Power Meghnaghat Limited	Number of Shares	Face Value	% of holding	
			31-Mar-25	30-Jun-24
Orion Pharma Limited	95,000,000	950,000,000	95.00%	95.00%
Integral Energy Limited	3,000,000	30,000,000	3.00%	3.00%
Jafflong Tea Company Limited	500,000	5,000,000	0.50%	0.50%
Mr. Mohammad Obaidul Karim	500,000	5,000,000	0.50%	0.50%
Mr. Salman Obaidul Karim	600,000	6,000,000	0.60%	0.60%
Mrs. Arzuda Karim	350,000	3,500,000	0.35%	0.35%
Haarhuis Generation B.V.	50,000	500,000	0.05%	0.05%
Total	100,000,000	1,000,000,000	100%	100%

Dutch Bangla Power & Associates Limited	Number of Shares	Face Value	% of holding	
			31-Mar-25	30-Jun-24
Orion Pharma Limited	6,700,000	67,000,000	67.00%	67.00%
Shenzhen Nanshan Power Co. Ltd.	50,000	500,000	0.50%	0.50%
Mohammad Obaidul Karim	100,000	1,000,000	1.00%	1.00%
Salman Obaidul Karim	3,087,500	30,875,000	30.88%	30.88%
Orion Tea Company Ltd.	50,000	500,000	0.50%	0.50%
Jafflong Tea Co. Ltd.	2,500	25,000	0.03%	0.03%
Mrs. Arzuda Karim	10,000	100,000	0.10%	0.10%
Total	10,000,000	100,000,000	100%	100%

18. Reserves

Fair value gain/(loss) on investment in associate (Note -18.1)	1,639,214,428	2,033,798,895
Fair value gain /(loss) on marketable securities (Note -18.2)	(14,183,886)	(11,606,178)
Share of other comprehensive income of associate (Note - 18.3)	7,089,341	6,774,874
Revaluation surplus on property plant and equipment (Note -18.4)	1,649,283,383	1,654,377,559
	3,281,403,266	3,683,345,150

SL No.	Particulars	Amount in BDT	
		31-Mar-25	30-Jun-24
18.1	Fair value gain on investment in associate		
	Opening balance	2,033,798,895	1,400,700,294
	Fair value gain/ (loss) during the period	(394,584,467)	633,098,601
		1,639,214,428	2,033,798,895
18.2	Fair value gain/(loss) on marketable securities		
	Opening balance	(11,606,178)	(7,704,833)
	Adjustment of sale of marketable securities	1,350	2,860,258
	Fair value gain/(loss) on marketable securities (Note - 18.2.1)	(2,865,470)	(7,195,085)
	Transferred to deferred tax assets/(liabilities)	286,412	433,483
		(14,183,886)	(11,606,178)
18.2.1	Fair value gain/(loss) on marketable securities during the period		
	Unrealized gain/(loss) position (closing)	(15,759,873)	(12,895,753)
	Unrealized gain/(loss) position (opening)	(12,895,753)	(8,560,925)
	Total change during the period	(2,864,120)	(4,334,828)
	Fair value adjustment for sale of securities (realized loss)	(1,350)	(2,860,258)
	Unrealized gain/(loss) during the period	(2,865,470)	(7,195,085)
18.3	Share of other comprehensive income		
	Opening balance	6,774,874	6,737,875
	Add: Addition during the period	314,467	36,999
		7,089,341	6,774,874
18.4	Revaluation surplus on property plant & equipment		
	Opening balance	1,654,377,559	1,667,479,327
	Adjustment during the period to retained earnings for depreciation	(5,727,826)	(14,040,509)
	Adjustment of deferred tax on revaluation surplus	633,650	938,741
		1,649,283,383	1,654,377,559
18.a	Reserve		
	Fair value gain on investment in associates (Note - 18a.1)	1,639,214,428	2,033,798,894
	Fair value gain/(loss) on marketable securities (Note - 18a.2)	(14,183,885)	(11,606,177)
	Share of other comprehensive income (Note - 18a.3)	7,089,341	6,774,874
	Revaluation surplus on property plant & equipment (Note - 18a.4)	1,301,290,072	1,304,880,755
		2,933,409,956	3,333,848,346
18a.1	Fair value gain on investment in associates		
	Opening balance	2,033,798,894	1,400,700,294
	Fair value gain/(loss) during the period	(394,584,467)	633,098,601
		1,639,214,428	2,033,798,894
18a.2	Fair value gain/(loss) on marketable securities		
	Opening balance	(11,606,177)	(7,704,832)
	Adjustment for marketable securities	1,350	2,860,258
	Fair value gain/(loss) on marketable securities D/Y (Note - 18a.2.1)	(2,865,470)	(7,195,085)
	Transferred to deferred tax assets/(liabilities)	286,412	433,483
		(14,183,885)	(11,606,177)

SL No.	Particulars	Amount in BDT	
		31-Mar-25	30-Jun-24
18a.2.1	Fair value gain/(loss) on marketable securities during the period		
	Unrealized gain/(loss) position (closing)	(15,759,873)	(12,895,753)
	Unrealized gain/(loss) position (opening)	(12,895,753)	(8,560,925)
	Fair value adjustment for sale of securities realized	(1,350)	(2,860,258)
	Unrealized gain/(loss) during the period	(2,865,470)	(7,195,085)
18a.3	Share of other comprehensive income		
	Opening balance	6,774,874	6,737,875
	Add: Addition during the period	314,467	36,999
		7,089,341	6,774,874
18a.4	Revaluation surplus on property plant & equipment		
	Opening balance	1,304,880,755	1,310,200,284
	Adjustment during the period to retained earnings for depreciation	(4,224,332)	(6,258,270)
	Adjustment of deferred tax on revaluation surplus	633,650	938,741
		1,301,290,072	1,304,880,755
19.	Retained earnings		
	Opening balance	7,499,339,162	7,400,327,363
	Net profit after tax	(41,371,610)	318,117,433
	Dividend for the period	(234,000,000)	(234,000,000)
	Adjustment for depreciation on revaluation surplus	5,727,826	14,040,509
	Adjustment for Right of use Assets	-	853,857
		7,229,695,378	7,499,339,162
19.a	Retained Earnings		
	Opening balance	961,565,844	973,857,096
	Net profit after tax	96,949,135	214,596,621
	Dividend for the period	(234,000,000)	(234,000,000)
	Adjustment for depreciation on revaluation surplus	4,224,332	6,258,270
	Adjustment for Right of use Assets	-	853,857
		828,739,312	961,565,844
20.	Non-controlling interest		
	Opening balance	1,543,272,725	1,509,624,870
	Share of operating profit	(51,912,402)	33,647,855
	Closing balance	1,491,360,323	1,543,272,725
21	Syndicated loan and other long term loans		
	Agrani Bank Ltd. -BMRE	5,150,955,908	4,737,011,986
	Social Islami Bank Ltd	1,492,752,738	1,425,931,955
	Term Loan -SBLC Agrani Bank Ltd	3,540,000,000	3,540,000,000
	Term Loan Capital Machinery - UPAS L/C	-	37,996,000
	AL-Arafa Islami Bank Ltd.	2,374,424,555	2,217,169,601
	ODDO BHF AG Finance	-	67,349,871
	Rupali Bank Ltd.	3,073,229,733	2,786,902,839
	Janata Bank Ltd	5,094,924,055	4,598,670,931
	Agrani Bank Ltd.	2,411,469,311	2,520,037,506
		23,137,756,300	21,931,070,689
	Less: Current portion of long term loan (Note 21.1)	-	(67,349,871)
		23,137,756,300	21,863,720,817
21.1	Current portion of long term loan		
	ODDO BHF AG Finance	-	67,349,871
		-	67,349,871

SL No.	Particulars	Amount in BDT	
		31-Mar-25	30-Jun-24
21.a	Long term loan		
	Agrani Bank Ltd. -BMRE	5,150,955,908	4,737,011,986
	Social Islami Bank Ltd.	1,492,752,738	1,425,931,955
	Term Loan -SBLC Agrani Bank Ltd.	3,540,000,000	3,540,000,000
	Term Loan Capital Machinery - UPAS L/C	-	37,996,000
	AL-Arafa Islami Bank Ltd.	2,374,424,555	2,217,169,601
	ODDO BHF AG Finance	-	67,349,871
	Rupali Bank Ltd.	3,073,229,733	2,786,902,839
	Janata Bank Ltd	5,094,924,055	4,598,670,931
	Agrani Bank Ltd.	2,411,469,311	2,520,037,506
		23,137,756,300	21,931,070,689
	Less: Current portion of long term loan (Note 21.a.1)	-	(67,349,871)
		23,137,756,300	21,863,720,817
21.a.1	Current portion long term loan		
	ODDO BHF AG Finance	-	67,349,871
		-	67,349,871
22	Lease obligation		
	Phoenix Finance & Investment Ltd.	-	272,122
	Lease obligation (Office rent)	46,912,368	27,385,897
		46,912,368	27,658,019
	Current portion of lease obligation (22.1)	(15,407,808)	(13,943,551)
		31,504,560	13,714,468
22.1	Current portion of lease obligation		
	Phoenix Finance & Investment Ltd.	-	272,122
	Lease obligation (Office rent)	15,407,808	13,671,429
		15,407,808	13,943,551
23	Deferred tax liability		
	Opening balance	315,432,155	157,696,141
	Adjustment for deferred tax expenses /(income) (Note-23.1)	65,337,625	159,108,238
	Adjustment for deferred tax on revaluation surplus (Note-23.2)	(920,062)	(1,372,223)
		379,849,718	315,432,156
23.1	Adjustment during the year on deferred tax on PPE		
	Deferred tax liability on PPE (closing)	334,648,829	269,311,204
	Deferred tax liability on PPE (opening)	269,311,204	110,202,966
	Deferred tax expenses/(income)	65,337,625	159,108,238

Particular	WDV as on 31 March 2025		Amount in BDT	
	Tax Base	Accounting Base	Deferred Tax Liability as on 31 March 2025	Deferred Tax Liability as on 30 June 2024
Written down value of property plant and equipment	9,211,999,474	10,699,327,603	(334,648,829)	(269,311,204)

23.2 Adjustment of deferred tax on revaluation Surplus

Deferred tax liability on revaluation surplus (Closing) (Note-23.2.1)	45,200,889	46,120,951
Deferred tax liability on revaluation surplus (Opening)	46,120,951	47,493,175
Deferred tax expenses/(income)	(920,062)	(1,372,223)

SL No.	Particulars	Amount in BDT	
		31-Mar-25	30-Jun-24

23.2.1 Adjustment of deferred tax on revaluation surplus

Particulars	WDV as on 31 March 2025		Amount in BDT	
	Tax Base	Accounting Base	Deferred Tax Liability as on 31 March 2025	Deferred Tax Liability as on 30 June 2024
Revaluation reserved on land & land development	-	1,298,728,729	(38,961,862)	(38,961,862)
Revaluation reserved factory & office building	-	41,076,011	(6,161,402)	(6,660,975)
Revaluation reserved plant & machinery	-	11,024,088	(1,653,613)	(1,787,690)
Revaluation reserve on marketable securities	-	(15,759,873)	1,575,987	1,289,575
Total	-	1,335,068,955	(45,200,889)	(46,120,951)

24. Short term loans

Cash credit (Hypo) Agrani Bank Ltd.	350,497,219	359,821,487
LTR Agrani Bank Ltd.WASA Corporate Branch	143,327,287	143,233,969
Loan against marketable securities	53,121,664	53,121,664
	546,946,170	556,177,120

25 Trade and other payables

Goods suppliers & manufacturer	5,637,672,547	5,096,894,653
Other payable	376,871,300	327,752,169
Current account with inter companies (Note -25.1)	1,114,609,881	1,039,045,934
	7,129,153,729	6,463,692,757

25.1 Current account with inter companies

Orion Capital Ltd.	18,420,000	18,420,000
Orion Oil & Shipping Ltd.	1,093,189,881	1,017,625,934
Orion Ship Management Ltd.	3,000,000	3,000,000
	1,114,609,881	1,039,045,934

25.a Trade and other payables

Goods suppliers & manufacturer	410,356,800	382,449,535
Other payables	81,227,612	67,817,868
	491,584,412	450,267,403

26 Employee benefits

Workers welfare fund (Note -26.1)	16,467,347	15,817,871
Bangladesh workers welfare foundation (Note -26.2)	19,804,286	18,947,348
Workers profit participation fund (Note -26.3)	114,423,260	112,469,234
	150,694,892	147,234,452

26.1 Workers welfare fund

Opening balance	15,817,871	13,198,802
Add: Addition for the period	856,937	2,619,068
Less: Payment during the period	(207,461)	-
	16,467,347	15,817,871

26.2 Bangladesh workers welfare foundation

Opening balance	18,947,348	19,897,506
Add: Addition for the year	856,937	2,619,068
Less: Payment during the period	-	(3,569,226)
	19,804,286	18,947,348

SL No.	Particulars	Amount in BDT	
		31-Mar-25	30-Jun-24
26.3	Workers profit participation fund		
	Opening balance	112,469,234	96,300,070
	Add: Addition for the year	6,855,500	20,952,547
	Less: Payment during the period	(4,901,474)	(4,783,384)
		114,423,260	112,469,234
26.a	Employee benefits		
	Workers welfare fund (Note -26.a.1)	5,921,504	5,064,567
	Bangladesh workers welfare foundation (Note -26.a.2)	11,615,156	10,758,218
	Workers profit participation fund (Note -26.a.3)	41,716,855	34,861,355
		59,253,515	50,684,141
26.a.1	Workers welfare fund		
	Opening Balance	5,064,567	3,131,342
	Addition during the period	856,937	1,933,225
	Payment during the period	-	-
		5,921,504	5,064,567
26.a.2	Bangladesh workers welfare foundation		
	Opening balance	10,758,218	10,970,408
	Addition for the period	856,937	1,933,225
	Payment during the period	-	(2,145,415)
		11,615,156	10,758,218
26.a.3	Workers profit participation fund		
	Opening Balance	34,861,355	19,395,555
	Addition during the period	6,855,500	15,465,800
		41,716,855	34,861,355
	WPPF is charged @ 5% of net profit before tax as per labour law Act 2006 (Amended in 2013) whereas 80% is allocated to "Workers profit participation fund" 10% to "Employee welfare fund" and 10% to "Bangladesh workers welfare foundation".		
27.	Accrued expenses		
	Salary and wages payable	95,528,888	96,402,075
	Director remuneration payable	23,481,459	11,462,918
	Depot expenses payable	2,195,420	1,813,600
	Telephone & mobile bill payable	3,363,629	4,193,441
	Payable for final settlement of employee	15,431,068	21,598,569
	Utilities payable	10,381,684	11,681,502
	Provision for income tax (Note 27.1)	316,792,832	304,490,093
	Corporate governance audit fees	-	69,000
	Statutory Audit fees	-	1,435,000
	Interest payable on syndicate loan	2,548,000	3,618,656
	Retention money	3,618,656	2,548,000
		473,341,636	459,312,854
27.1	Provision for income tax		
	Opening balance	304,490,093	435,261,134
	Add: Addition during the period	15,302,738	22,154,543
		319,792,832	457,415,677
	Less: Payment/AIT adjustment during the period	(3,000,000)	(152,925,584)
		316,792,832	304,490,093

SL No.	Particulars	Amount in BDT	
		31-Mar-25	30-Jun-24
27.a	Accrued expenses		
	Salary and wages payable	79,543,770	74,620,291
	Director remuneration payable	300,000	300,000
	Depot expenses payable	2,195,420	1,813,600
	Telephone & mobile bill payable	3,363,629	4,193,441
	Payable for final settlement of employee	15,431,068	12,000,037
	Utilities payable	10,381,684	11,681,502
	Provision for income tax (Note - 26.a.1)	316,792,832	304,490,093
	Statutory Audit fees	-	690,000
	Corporate governance audit fees	-	69,000
		428,008,403	409,857,964
27.a.1	Provision for income tax		
	Opening balance	304,490,093	435,261,134
	Add: Addition during the period	15,302,738	22,154,543
		319,792,832	457,415,677
	Less: Payment/AIT adjustment during the period	(3,000,000)	(152,925,584)
	Closing balance	316,792,832	304,490,093

SL No.	Particulars	Amount in BDT	
		July 2024 to March 2025	July 2023 to March 2024
28. Revenue from net sales			
	Local sales	2,362,333,655	2,741,449,992
	Export sales	172,105,953	102,503,567
	Revenue from power generation (Note-28.1)	817,570,779	4,936,544,159
		3,352,010,387	7,780,497,718
28.1 Revenue from power generation			
	Reference energy price (variable - O&M)	137,345,898	845,955,380
	HFO received from OOSL & BPDB	680,224,881	4,090,588,779
		817,570,779	4,936,544,159
28.a Revenue from net sales			
	Local sales	2,362,333,655	2,741,449,992
	Export sales	172,105,953	102,503,567
		2,534,439,608	2,843,953,559
29 Financial expense			
	Agrani Bank Limited, Cash Credit (Hypo.)	33,613,562	26,476,420
	Agrani Bank Limited, LTR	13,853,165	10,821,503
	Phoenix Finance & Investments Ltd.	-	34,243,995
	Finance cost on lease obligation (Office rent)	2,220,147	2,109,441
	Bank Charge ,commission & Fees	20,214,869	20,861,239
	Interest on Long Term Borrowing	64,955,963	5,550,418
	Social Islamic Bank Ltd.	100,649,865	-
		235,507,570	100,063,016
29a Financial expenses			
	Agrani Bank Limited, Cash Credit (Hypo.)	33,613,562	26,476,420
	Agrani Bank Limited, LTR	13,853,165	10,821,503
	Phoenix Finance & Investments Ltd.	-	34,243,995
	Finance cost on lease obligation (Office rent)	2,220,147	2,109,441
	Bank Commision, Fees, VAT and Other Charges	9,394,948	927,175
	Social Islamic Bank Ltd.	100,649,865	-
		159,731,686	74,578,534
30. Interest & other income			
	Interest on FDR	5,002,624	2,204,229
	Dividend income	2,621,375	303,275
	Others Income	4,776,809	5,808,975
	Cash Incentive	3,616,000	8,847,400
	Gain/(loss) on sale of marketable securities (Note 30.a.1)	(1,350)	(40,203)
		16,015,459	17,123,676
30.a Interest & other income			
	Interest on FDR	5,002,624	2,204,229
	Dividend income	2,621,375	303,275
	Others Income	4,776,809	3,602,844
	Cash Incentive	3,616,000	8,847,400
	Gain/(loss) on sale of marketable securities (Note 30.a.1)	(1,350)	(40,203)
		16,015,459	14,917,546
30a.1 Income on sale of marketable securities			
	Gain/(loss) on sale of marketable securities	-	(38,353)
	Interest on portfolio credit and others	(1,350)	(1,850)
		(1,350)	(40,203)

SL No.	Particulars	Amount in BDT	
		July 2024 to March 2025	July 2023 to March 2024
31. Current tax			
Profit before tax		171,387,499	406,110,524
Add: Accounting depreciation		432,461,581	209,896,656
Less: Tax depreciation		(686,085,627)	(135,675,619)
Rights of Use Assets		(17,559,231)	-
Taxable income		(99,795,778)	480,331,561

Income tax provision

Particulars	Taxable Income	Tax Amount	
		31-Mar-25	31-Mar-24
Income tax on taxable profit	(117,671,548)	(23,534,310)	102,722,309
Income tax on export net profit	11,638,395	1,163,839	1,646,695
Cash Incentive	3,616,000	361,600	884,740
Income tax on dividend received	2,621,375	524,275	60,655
Total	(99,795,778)	(21,484,595)	105,314,399

Minimum Tax

Calculation of gross receipt

Revenue from net sales	2,534,439,608	2,843,953,559
Interest on FDR	5,002,624	2,204,229
Dividend income	2,621,375	303,275
Others income	4,776,809	3,602,844
Cash Incentive	3,616,000	8,847,400
Total Gross Receipts	2,550,456,416	2,858,911,307
Minimum Tax (0.60% On Total Gross Receipts)	15,302,738	17,153,468
Tax provision whichever is higher	15,302,738	105,314,399

Income tax provision is higher between tax at regular rate on income and minimum tax on gross receipts U/S 163 of ITA 2023. Hence tax at regular rate is accounted for as it is higher than the minimum tax.

32 Earnings per share (EPS)

The computation is given below:

Net profit after tax	(41,371,610)	386,134,140
Ordinary shares outstanding during the period	234,000,000	234,000,000
Earning per share	(0.18)	1.65

Revenue of Orion Pharma Ltd. during the reporting period has decreased compared to the same nine-month period in the previous period, due to the country's economic situation. Furthermore, two subsidiary power generation companies have remained idle since September 2024 because no requisition for electricity was received from the Bangladesh Power Development Board (BPDB) even though there are no capacity payments, and these power plants have the lowest tariff rates.

32a Earnings per share

The computation is given below:

Net profit after tax	96,949,135	323,779,340
Ordinary shares outstanding during the period	234,000,000	234,000,000
Earnings per share	0.41	1.38

A large amount of non-current assets was transferred to Property, Plant, and Equipment on June 30, 2024, from Construction Work in Progress. As a result, more depreciation expense was charged compared to the previous period, which is one of the main reasons for the decline in EPS.

SL No.	Particulars	Amount in BDT	
		July 2024 to March 2025	July 2023 to March 2024
33. Net Assets Value (NAV) Per Share		31-Mar-25	30-Jun-24
Total Assets		54,652,295,638	53,185,508,321
Total Liabilities		33,784,304,968	31,645,931,982
Net Assets		20,867,990,670	21,539,576,339
No of shares		234,000,000	234,000,000
Net Assets Value (NAV) Per Share		89.18	92.05
33a Net Assets Value (NAV) Per Share			
Total Assets		39,494,236,448	38,452,129,354
Total Liabilities		25,375,195,155	23,799,823,138
Net Assets		14,119,041,293	14,652,306,216
No of shares		234,000,000	234,000,000
Net Assets Value (NAV) Per Share		60.34	62.62
34. Clause No. 5 (2) (e) of Notification No. BSEC/CMRRCD/2006-158/208/Admin/81, Dated: 20 June 2018: Reconciliation of Net operating cash flow under Indirect Method:			
Net profit before tax		(18,845,649)	484,905,519
Workers profit participation fund		8,569,375	20,305,526
Interest & other income		(16,015,459)	(14,917,546)
Financial expenses		235,507,569	97,856,886
Depreciation		483,929,662	418,404,916
Increase/(Decrease) in inventory		58,764,923	(104,364,351)
Increase/(Decrease) in receivables		(330,713,546)	2,224,695,215
Increase/(Decrease) in advance deposit & prepayments		150,182,836	(48,696,952)
Increase/(Decrease) in payable		667,301,356	(2,255,043,842)
Increase/(Decrease) in accrued expenses		32,326,494	28,812,811
Income taxes paid		(37,529,764)	(127,964,951)
Net cash flow from operating Activities		1,233,477,797	723,993,232
34.1 Net operating cash flow per share		5.27	3.09
NOCFPS increased to 5.27 than 3.09 of the previous corresponding period. During the period cash paid for operating expenses is decreased than the previous corresponding period.			
34.a Clause No. 5 (2) (e) of Notification No. BSEC/CMRRCD/2006-158/208/Admin/81, Dated: 20 June 2018: Reconciliation of Net operating cash flow under Indirect Method:			
Net profit before tax		171,387,499	406,110,524
Workers profit participation fund		8,569,375	20,305,526
Interest & other income		(16,015,459)	(14,917,546)
Financial expenses		159,731,686	74,578,534
Depreciation		432,461,581	209,896,656
Increase/(Decrease) in inventory		(34,477,143)	32,302,358
Increase/(Decrease) in receivables		67,877,070	(50,367,370)
Increase/(Decrease) in advance, deposit & prepayments		169,053,018	(36,790,019)
Increase/(Decrease) in payable		41,317,009	31,432,069
Increase/(Decrease) in accrued expenses		5,847,700	(2,537,500)
Income taxes paid		(37,529,764)	(127,964,951)
Net cash flow from operating activities		968,222,572	542,048,281
34a.1 Net operating cash flow per share		4.14	2.32

Sd/-
Chairman

Sd/-
Managing Director

Sd/-
Director

Sd/-
Chief Financial Officer

Sd/-
Company Secretary